Pioneering a paradigm shift in cardiovascular care, our multi-needle catheter system is dedicated to advancing gene therapy for atrial fibrillation. We seek to seamlessly connect cutting-edge research with practical market solutions by drastically reducing development time and costs. Collaborating with researchers and companies in this domain, our device promises to augment the convenience of healthcare providers by offering unprecedented precision and therapeutic delivery efficiency. Positioned at the forefront of cardiovascular innovation, our venture addresses critical challenges in the R&D-to-market transition of novel therapeutics. As the healthcare landscape evolves, our multi-needle catheter system emerges as a transformative force, ushering in a new era of efficiency and time-and-cost-effectiveness in the treatment of atrial fibrillation. With a commitment to revolutionizing cardiac care, our venture marks a pivotal step towards a future where advanced therapies are readily accessible, making a lasting impact on patient outcomes.